Why ELTON · Find the 1%

A million findings. Ten that matter.

Discovery is solved to the point of drowning. Scanners, feeds, and SBOM matching will bury a device program in findings on day one. The unsolved problem is telling which of them can actually hurt your device, and evidencing the difference for a regulator.

The objective, stated plainly

Find the 1% of findings that require fixing. Verify, with executed evidence, why the other 99% do not. Both halves are the product. Neither works without the other.

The real problem

You are not short on findings. You are short on verdicts.

Component matching casts a wide net on purpose. Run it across a full SBOM and years of CVE history and the raw list runs to the thousands per device. Almost none of it applies to your build, your configuration, or your reachable attack surface. Someone still has to say so, per finding, in writing.

The pile keeps growing

CVE volume climbs every year while analyst headcount does not. Manual triage was losing this race in 2023. It is not close anymore.

Silence is not a disposition

Skipping an irrelevant CVE feels efficient until an auditor asks why it was never assessed. A missing answer reads the same as a missed vulnerability.

Developers act on proof

Send engineering a queue of maybes and they will treat all of it as noise. Send ten verified exploits and they fix ten things. ELTON only sends what is proven.

Vulnerability vs weakness

Two words your backlog keeps confusing.

ELTON draws one line through every finding, and the line is exploitability on your device as it actually ships.

VULNERABILITY

Exploitable today

Reachable from the actual attack surface and substantiated by an executed test case on the device. This is the 1%. It gets a fix, a timeline, and a re-test that proves the fix worked.

WEAKNESS

Latent, tracked, not urgent

Real code, real flaw, no reachable path today. It stays in the twin and stays watched, because the next architecture change can promote it. It does not page an engineer tonight.

Which word applies cannot be settled by reading source code or quoting a severity score. Exploitability is a runtime question, so ELTON answers it at runtime: by attacking the running device, verifying the exploit remotely or over TestLink™ on your own bench.

The other 99%

Dismissed is not ignored. Dismissed is evidenced.

Every finding that misses the fix list gets a disposition with proof attached: the reason it does not apply, the test or analysis behind that reason, and a machine readable VEX status your customers can ingest. The 99% stop being a liability and become a record that you looked, tested, and can defend the call.

From the feed to a defensible answer CVE candidates matched to the SBOM: hundreds of thousands and climbing Digital twin: in your build, this version, this configuration? Reachable from the actual attack surface? Exploit executed on the device? The 1%: verified vulnerabilities working PoC, fix guidance, re-test on close The 99%: dispositioned with evidence reason, test, VEX status per finding
One feed in, two evidenced outputs out. Nothing exits the funnel without a status.

The short list often shrinks further. The dependency graph traces verified findings to shared root causes, so ten proven exploits can collapse into one engineering fix. Every disposition rests on executed evidence, holds to the Proof Over Probability standard, and publishes through living reports and VEX.

Get started

Find your 1%.

One device, one twin, one report: the short list that needs engineering time, and the evidenced record for everything that does not.

Automate medical device vulnerability discovery and verification. FDA §524B methodologyExploitability proven on-device95% faster than legacy testing Book a Demo
Platform
Platform OverviewDigital TwinAutonomous TestingExploitability VerificationVulnerability GraphRemediation OptimizationELTON TestLink™Lifecycle & MetricsCVSSv4 Migration
Solutions
FDA §524BEU MDR/CRAEU REDNIS2IMDRF N60 / N73Postmarket SurveillanceIncident Response
Why ELTON
Why ELTONPricing
Resources
Intelligence & BlogRegulatory GuidesWebinarsWhitepapers
Company
AboutLeadershipCareersContact Book a Demo